钙调神经磷酸酶抑制剂联合乌司奴单抗诱导治疗急性重度溃疡性结肠炎的疗效
急性重度溃疡性结肠炎(ASUC)一线治疗为静脉糖皮质激素,无效时可考虑环孢素或英夫利西单抗。本文为回顾性研究,评估钙调神经磷酸酶抑制剂桥接乌司奴单抗在ASUC患者中的疗效与安全性。
要点
- ASUC一线治疗为静脉糖皮质激素,无效时可考虑环孢素或英夫利西单抗。
- 环孢素在ASUC中常作为硫嘌呤类药物的桥接治疗。
- 本文回顾性评估钙调神经磷酸酶抑制剂桥接乌司奴单抗治疗ASUC的疗效与安全性。
核心结论
- 本文为回顾性研究,评估钙调神经磷酸酶抑制剂桥接乌司奴单抗在ASUC患者中的疗效与安全性。
研究设计与样本
- 回顾性研究,评估钙调神经磷酸酶抑制剂桥接乌司奴单抗在ASUC患者中的疗效与安全性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ulcerative colitis is a chronic inflammatory bowel disease. Approximately 20% of patients experience an acute severe attack during their life. In acute severe ulcerative colitis (ASUC), first-line therapy is intravenous (IV) steroids. In the absence of clinical improvement, 2 medical options can be considered: ciclosporin or infliximab.1 In ASUC, ciclosporin is commonly used as a bridging therapy for thiopurines. Pellet et al2 found that the same bridge strategy with vedolizumab was effective and can avoid colectomy. Given that an increasing number of patients with ASUC have been exposed to thiopurines, vedolizumab, and anti-tumor necrosis factor biologic therapies, newer approaches are needed in these patients, such as tofacitinib or ustekinumab. Ustekinumab, an antagonist of the p40 subunit of interleukin-12 and interleukin-23, has shown efficacy in ulcerative colitis and can be given in this indication.3 In this retrospective study, we evaluate the efficacy and safety of a bridge from calcineurin inhibitor to ustekinumab in patients with ASUC.
引用
- Veyrard P, Pellet G, Laharie D, et al. Efficacy of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022. PMID: 35307594. doi:10.1016/j.cgh.2022.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。